Candesartan

Cardiovascular Drug Reviews

Volumn 22, Issue 4, 2004, Pages 263-284

  Gleiter, Christoph H ^a   Jägle, Christine ^a   Gresser, Ursula ^b   Mörike, Klaus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiotensin II antagonists; Candesartan; Candesartan cilexetil; Heart Failure; Hypertension; TCV 116

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIGOXIN; ENALAPRIL; EPROSARTAN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FELODIPINE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LITHIUM; LOSARTAN; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PLACEBO; PRODRUG; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; WARFARIN;

ADULT; AGE; AGED; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANIMAL TISSUE; BACKACHE; BILIARY EXCRETION; CLINICAL TRIAL; COUGHING; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEMALE; GENDER; HEADACHE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TOXICITY; MALE; METABOLIC SYNDROME X; MOUSE; NEPHRITIS; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; RAT; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION;

EID: 12244268928     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2004.tb00146.x     Document Type: Review

References (105)

1. Andersen NH, Knudsen ST, Poulsen PL, et al. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: Rationale and design. J Renin Anglotensin Aldosterone Syst 2003;4:96-99.
2. Anderson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998;7:53-59.
3. Anonymus: Angiotensin-II-Rezeptor-Blocker bei Herzinsuffizienz. Die CHARM-Studien. Arzneimittelbrief 2003;37:90-92.
4. Asmar R, Lacourcière Y. A new approach to assessing antihypertensive therapy: Effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000;18:1683-1690.
5. Bakris G, Gradman A, Reif M, et al. CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001;3:16-21.
6. Basile G, Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro V. Candesartan cilexetil-induced severe hepatotoxicity. J Clin Gastroenterol 2003;36:273-275.
7. Baumgart P, Reismann J, Pohlmeyer H, Düsing R. Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: Better efficacy and tolerance. SWITCH study (German study segment). Dtsch Med Wochenschr 2001;126:547-550.
8. Belcher G, Hübner R, George M, et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997;11(Suppl 2):S85-S89.
9. Belcher G, Lunde H, Elmfeldt D, et al. The combination tablet of candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg has a tolerability profile similar to that of placebo. J Hypertens 2000;18(Suppl 2):S94.
10. Belz GG. Pharmacological differences among angiotensin II receptor antagonists. Blood Pressure 2001;10(Suppl 2):13-18.
11. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997;11(Sep,Suppl 2):S45-S47.
12. Belz GG, Butzer R, Kober S, Mutschler E. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. J Cardiovasc Pharmacol 2002;39(4):561-568.
13. Bosch X. Henoch-Schönlein purpura induced by losartan therapy. Arch Int Med 1998;158:191.
14. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912.
15. Campbell M, Sonkodi S, Soucek M, Wiecek A. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens 2001;23:345-355.
16. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
17. Cuspidi C, Muiesan ML, Valagussa L, et al. CATCH investigators: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20:2293-2300.
18. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001;14:174-182.
19. Degl'Innocenti A, Elmfeldt D, Hansson L, et al. Cognitive function and health-related quality of life in elderly patients with hypertension-baseline data from the study on cognition and prognosis in the elderly (SCOPE). Blood Press 2002;11:157-165.
20. Derosa G, Cicero AF, Ciccarelli L, Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003;25:2006-2021.
21. De Zeeuw D, Remuzzi KW. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997;11(Suppl 2):S37-S42.
22. 1-Rezeptor-Antagonisten. Dtsch Med Wochenschr 2003;128:2313-2318.
23. Easthope SE, Jarvis B. Candesartan cilexetil. An update of its use in essential hypertension. Drugs 2002;62: 1253-1287.
24. Eguchi K, Kario K, Shirnada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol 2003;92:621-624.
25. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997;11(Suppl 2):S49-S53.
26. Erdmann E, George M. Voet B, et al. The safety and tolerability of candesartan cilexetil in CHF. J RAAS 2000;1(Suppl 1):31-36.
27. Etminan M, Mitchell A, Levine MA, et al. Efficacy of angiotensin II receptor antagonists in preventing headache. Am J Med 2002;112:642-646.
28. Fridman KU, Wysocki M, Friberg PR, Andersson OK. Candesartan cilexetil in hypertension: Effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system. Blood Press 1999;8:242-247.
29. Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hypertens 2000;13:1045-1048.
30. 1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. Blood Press 2002;11:244-252.
31. Fuchs B, Breithaupt-Grögler K., Belz GG, et al. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J Pharm Pharmacol 2000;52:1075-1083.
32. Gleiter CH, Mörike K. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002;41:7-17.
33. Granger B, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000;139:609-617.
34. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003;362:772-776.
35. Grassi G, Seravalle G, Dell'Oro R, et al. CROSS Study. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 2003;21:1761-1769.
36. Hanatani T, Fukuda T, Ikeda M, et al. CYP 2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J 2001;1:288-292.
37. 1 receptor blockers. Blood Pressure 2001;10(Suppl 3):33-39.
38. Hayashi T, Sohmiya K, Ukimura A, et al. Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 2003;89:1236-1242.
39. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, Redon J, Asmar R, Hedner T. Effect Study Group: The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 2001;10:43-51.
40. Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M, et al. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Eur J Clin Pharmacol 1998;54:341-345.
41. 2-receptor-dependent mechanism. Hypertension 2003;41: 1092-1095.
42. Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997;19:1079-1099.
43. Inada Y, Ojima M, Kanagawa R, et al. Pharmacologic properties of candesartan cilexetil - possible mechanisms of long-acting antihypertensive action. J Hum Hypertens 1999;13(Suppl 1):S75-80.
44. Kloner RA, Weinberger M, Pool JL, et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001;87:727-731.
45. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-910.
46. Kondo J, Sone T, Tsuboi H, et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J 2003;146:e20.
47. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999;12:1181-1187.
48. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive treatment and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-1574.
49. Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
50. MacGregor GA, Viskoper JR, Antonios TF, He FJ. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. Hypertension 2000;36:454-460.
51. 1) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000;13:504-511.
52. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 2000;22:1186-1203.
53. Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002;147:617-618.
54. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003;5:669-677.
55. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998;56:847-869.
56. McFayden RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 1994;12:1333-1338.
57. 1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens 2000;14:263-269.
58. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999;100:1056-1064.
59. McKelvie R, Rouleau JL, White M. Comparative impact on enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003;24: 1727-1734.
60. McMurray JJV. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart 2001;86:97-103.
61. McMurray JJC, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-771.
62. Mitrovic V, Willenbrock R, Miric M, et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am Heart J 2003;145:D1-D9.
63. Mogensen CE, Neldam S, Tikkanen I, et al. for the CALM group: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000;321: 1440-1444.
64. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544-549.
65. Morton A, Muir J, Lim D. Rash and acute nephritic syndrome due to candesartan. Br Med J 2004;328:25.
66. Myou S, Fujimura M, Kamio Y, et al. Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to metacholine in patients with bronchial asthma. Br J Clin Pharmacol 2002;54:622-626.
67. Nakaya H, Sasamura H, Kitamura Y, Amemiya T, et al. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens Res 1999;22:303-12.
68. Neldam S, Forsen B. Antihypertensive treatment in elderly patients aged 75 years or over: A 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001;18:225-232.
69. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: A review of its preclinical pharmacology. J Human Hypertens 1997;11(Suppl 2):S9-S17.
70. Nishimura Y, Ito T, Hoe K, Saavedra JM. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000;871:29-38.
71. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000;31:2478-2486.
72. Noda M, Shibouta Y, Inada Y, et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993;46:311-318.
73. Ohma KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension - comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000;9:214-220.
74. 1 receptor. Eur J Pharmacol 1997;319:137-146.
75. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002;445:151-152.
76. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-766.
77. Pfeffer MA, McMurray JJV, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
78. Pfister M, Schaedeli F, Frey FJ, et al. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Br J Clin Pharmacol 1999;47:645-647.
79. 2 receptors. J Renin Angiotensin Aldosterone Syst 2002;3:36-39.
80. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-752.
81. Pitt B, Poole-Wilsou P, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-1587.
82. Porcellati C, Omboni S. Switching from ACE inhibitors, beta-blockers, calcium antagonists or diuretics to candesartan improves efficacy and tolerability. Blood Press 2002;11:310-319.
83. Preston RA, Baltodano NM, Alonso AB, Epstein M. Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. J Clin Pharmacol 2002;42:754-761.
84. Riegger GAJ, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999;100:2224-2230.
85. 1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor. J Clin Endocrinol Metab 2003;88:3878-3873.
86. Schrader H, Stovner LJ, Heide G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril). Br Med J 2001;322:19-22.
87. Schrader J, Lüders S, Kulschewski A, et al. The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-1703.
88. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild and moderate hypertension. J Hum Hypertens 1997;11(Suppl 2):S69-S73.
89. Sever PS, Chang CL. Discordant responses to two classes of drugs acting on the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst 2001;2:25-30.
90. Siegl PKS, Kivlighn SD, Broten TP, et al. Pharmacology of angiotensin II receptor antagonists: Comparison with renin inhibitors and angiotensin- converting enzyme inhibitors. Expert Opin Invest Drugs 1994;3:925-944.
91. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
92. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000;20:130-139.
93. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): Rationale and design. J Cardiac Failure 1999;3:276-282.
94. Summary of product characteristics (Fachinformation). www.fachinfo.de (access April 2004).
95. Takahashi T, Anzai T, Yoshikawa T, et al. Angiotensin receptor blockade improves myocardial beta-adrenergic receptor signaling in postinfarction left ventricular remodeling. J Am Coll Cardiol 2004;43:125-132.
96. Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001;104:281-285.
97. Tanser PH, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. Am J Hypertens 2000;13:214-218.
98. Timmermans PB, Wong PC, Chin AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
99. Tran D, Phoon S, Howes L. The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers. J Renin Angiotensin Aldosterone Syst 2001;2:199-203.
100. Tronvik E, Stovner, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003;289:65-69.
101. Uchida S, Watanabe H, Nishio S, et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype. Clin Pharmacol Ther 2003;74:505-508.
102. Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Human Hypertens 2001;15:475-480.
103. Wada T, Inada Y, Sanada T, et al. Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug. TCV-116, on production of aldosterone. Eur J Pharmacol 1994;253:27-34.
104. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781.
105. Zanchetti A, Omboni S. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group. Am J Hypertens 2001;14:129-134.